- CNX-774
-
- $2.00 / 1kg
-
2019-07-06
- CAS:1202759-32-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | CNX-774 Basic information |
| Product Name: | CNX-774 | | Synonyms: | CNX-774;4-[4-[[5-Fluoro-4-[[3-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide;4-(4-((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)-N-methylpicolinamide;4-[4-[[5-Fluoro-4-[[3-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide CNX-774;4-(4-((4-((3-Acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)-N-methylpicolinamid;2-Pyridinecarboxamide, 4-[4-[[5-fluoro-4-[[3-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl-;4-{4-[(4-{[3-(Acryloylamino)phenyl]amino}-5-fluoro-2-pyrimidinyl) amino]phenoxy}-N-methyl-2-pyridinecarboxamide;CNX774; CNX 774 | | CAS: | 1202759-32-7 | | MF: | C26H22FN7O3 | | MW: | 499.5 | | EINECS: | | | Product Categories: | Inhibitors;API | | Mol File: | 1202759-32-7.mol |  |
| | CNX-774 Chemical Properties |
| density | 1.383±0.06 g/cm3(Predicted) | | storage temp. | Store at -20° C | | solubility | Soluble in DMSO | | form | Powder | | pka | 13.22±0.70(Predicted) | | CAS DataBase Reference | 1202759-32-7 |
| | CNX-774 Usage And Synthesis |
| Uses | CNX-774 is an irreversible, orally active, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) and can be used for the treatment of rheumatoid arthritis (RA). | | Biological Activity | cnx-774 is an orally active and selective inhibitor of btk with ic50 value of <1 nm.bruton’s tyrosine kinase (btk) is an important enzyme in the b-cell antigen receptor (bcr) signaling pathway and also plays an important role in mast cell activation and b cell maturation.cnx-774 is an orally active, irreversible and selective btk inhibitor with ic50 value of <1 nm. cnx-774 formed covalent bond with the cys481 residue within the atp binding site of btk. in cellular assays, cnx-774 inhibited btk with ic50 values of 1-10 nm [1]. | | references | [1]. akinleye a, chen y, mukhi n, et al. ibrutinib and novel btk inhibitors in clinical development. j hematol oncol, 2013, 6: 59. |
| | CNX-774 Preparation Products And Raw materials |
|